CASI Pharmaceuticals (CASIF) Interest & Investment Income (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Interest & Investment Income came in at $10000.0 in Q3 2025, down 93.01% YoY from $143000.0 in Q3 2024, and down 77.78% on a QoQ basis from $45000.0 in Q2 2025.
CASI Pharmaceuticals (CASIF) Interest & Investment Income (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Interest & Investment Income data on file, last reported at $10000.0 in Q3 2025.
- Quarterly Interest & Investment Income fell 93.01% year-over-year to $10000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $262000.0 (changed N/A YoY) and the FY2024 annual result came in at $539000.0, down 14.31% from the prior year.
- Interest & Investment Income fell to $10000.0 in Q3 2025, from $45000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $143000.0 in Q3 2024 to a low of $10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Mar 31, 2024 | 131,000.00 |